Modified LDL Immune Complex Detection for Coronary Artery Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring modified LDL immune complexes are complex, time-consuming, and unreliable, particularly in studying large patient cohorts, due to interference from pre-formed immune complexes and the need for specific isolation and dissociation of antigens and antibodies, which limits the understanding of their role in chronic inflammatory processes like atherosclerosis.
Innovation Solution
A method involving the measurement of oxidized-LDL (ox-LDL) and advanced glycation endproduct-LDL (AGE-LDL) immune complexes in serum or plasma samples, using techniques such as PEG precipitation, affinity chromatography, and immunoassays to isolate and quantify these complexes, allowing for the prediction of coronary artery disease and type 1 diabetes complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional methods are used to measure modified LDL immune complexes, then measurement can be performed, but the process becomes complex and time-consuming requiring specific isolation and dissociation procedures
Solution Approach 1:
The patent extracts and measures only the modified LDL immune complexes from the complex serum matrix using specific antibodies that bind to modified LDL, eliminating the need for complex isolation and dissociation procedures while maintaining measurement accuracy
Solution Approach 2:
The patent uses specific antibodies as intermediaries to directly detect modified LDL immune complexes in serum, serving as a mediator that simplifies the measurement process by eliminating the need for complex sample preparation steps
2Measurement precision
If traditional methods are used to measure modified LDL immune complexes, then measurement can be performed, but reliability is reduced due to interference from pre-formed immune complexes
Solution Approach 1:
Instead of trying to eliminate interference from pre-formed immune complexes, the patent inverts the approach by using antibodies that specifically recognize and bind to modified LDL within the immune complexes, turning the interference into a target for measurement
Solution Approach 2:
The patent changes the measurement parameter from total immune complex levels to specific modified LDL immune complex levels using antigen-specific antibodies, thereby distinguishing target analytes from interfering substances and improving measurement reliability
3Measurement precision
If complex isolation and dissociation procedures are used, then modified LDL can be measured, but productivity decreases when studying large patient cohorts
Solution Approach 1:
The patent enables the measurement system to directly process serum samples without requiring complex manual isolation and dissociation procedures, allowing high-throughput automation and significantly improving productivity for large patient cohorts
Solution Approach 2:
The patent replaces complex mechanical isolation and dissociation procedures with an immunological detection system using specific antibodies, enabling direct measurement in serum and facilitating automated high-throughput processing
4Ease of operation
If cholesterol is used as a surrogate marker for modified LDL, then measurement is simplified, but measurement precision and predictive power are reduced
Solution Approach 1:
The patent changes the measurement parameter from total cholesterol levels to specific modified LDL immune complex levels using antigen-specific antibodies, providing more precise and predictive measurements while maintaining operational simplicity through direct immunoassay methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a reliable and efficient way to predict the risk of coronary artery disease and type 1 diabetes complications by accurately measuring ox-LDL and AGE-LDL immune complexes, exceeding the predictive power of classical risk factors and identifying high-risk individuals even at a young age.
Implementation Method 1
PEG precipitation
Implementation Method 2
affinity chromatography
Data Source
AI summary
The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes.